News

Blood pressure medication recall for cancer risk expanded – 10TV

A blood pressure medication recall has been expanded due to the possible inclusion of an impurity that could lead to cancer, given long-term exposure. It’s one of the dozens of such recalls which started in July 2018.

While these recalls have created a panic for some, experts say it’s important to note that it would likely take years of exposure to develop cancer and that quitting the medication without an alternative would be more dangerous.

Torrent Pharmaceuticals Limited announced Thursday it is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium / hydrochlorothiazide tablets, USP, after trace amounts of N-Methylnitrosobutyric acid (NMBA) was detected. NMBA is a known animal and potential human carcinogen, according to the Food and Drug Administration.

Advertisement – Story continues below

Torrent said it is only recalling lots containing NMBA that are above the acceptable daily intake levels by the FDA.

Here are the lots to look for

  • Losartan Potassium Tablets, USP 50mg, 1000 count
  • NDC: 13668-409-10
  • Batch No.: 4DU2E009
  • Expiration: 12/31/2020

Losartan Potassium Tablets, USP 100mg, 90 count

  • NDC: 13668-115-90
  • Batch No.: 4DU3E009
  • Expiration: 12/31/2020

Losartan Potassium Tablets, USP 100mg, 1000 count

  • NDC: 13668-115-10
  • Batch No.: 4DU3D018
  • Expiration: 02/28/2021

Losartan Potassium / Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count

  • NDC: 13668-116-90
  • Batch No.: BEF7D051
  • Expiration: 11/30/2020

Losartan Potassium / Hydrochlorothiazide Tablets, USP 100mg/25mg, 90 count

  • NDC: 13668-118-90
  • Batch No.: 4P04D007
  • Expiration: 07/31/2020

Nitrosamine impurities like NBMA, which have led to the recalls, may be generated when specific chemicals and reaction conditions are present in the manufacturing process of the drug’s active pharmaceutical ingredient, according to the FDA. It could also be due to the reuse of materials, such as solvents.

The risks of developing cancer from these are low and won’t happen overnight according to the FDA. The agency says if someone were to take the highest daily dose of Valsartan that contained NDMA, and took that medication for four years, the odds of getting cancer are an increased 1-in-8,000 patients.

Dr. Eugene Yang, a physician with UW Medicine in Seattle and an associate professor of Cardiology and Medicine at the University of Washington, said earlier this year that most patients don’t take the highest dosage, so even that 1-in-8,000 estimate is high.

Yang also said blood pressure is significantly elevated by discontinuing these medications, thereby increasing the risk of a heart attack or stroke. The general advice is to continue taking the medication until a doctor can prescribe an alternative.

©2019 by 10TV.com. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Tags
Show More

Related Articles

Back to top button
Close